» Articles » PMID: 19573542

Corticotropin Releasing Factor-induced ERK Phosphorylation in AtT20 Cells Occurs Via a CAMP-dependent Mechanism Requiring EPAC2

Overview
Specialties Neurology
Pharmacology
Date 2009 Jul 4
PMID 19573542
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

CRF-induced ERK phosphorylation has been shown to be an important mechanism underlying expression of pro-opiomelanocortin, a key precursor molecule in the hypothalamic pituitary adrenal axis. In AtT20 cells, CRF signalling has been investigated but the mechanism behind CRF-induced ERK activity is not fully understood. This paper elucidates the signalling cascade involved in this phenomenon. Involvement of CRF(1) receptor on ERK phosphorylation was shown by using CRF and urocortin 1. The lack of inhibitory effect of pertussis toxin and BAPTA-AM excluded involvement of G(i)-coupling and calcium mobilization respectively. In contrast, the process is suggested to be driven by cAMP since treatment of AtT20 cells with forskolin triggered strong ERK phosphorylation. Treatment with PKA inhibitors had a minor effect on CRF-induced ERK signalling while phosphorylation of CREB was completely abolished. This ruled out involvement of PKA and suggested a role for exchange protein directly activated by cAMP (EPAC). Moreover, an activator of EPACs 8-(4-methoxyphenylthio)-2'-O-methyladenosine-3',5'-cyclic monophosphate mimicked CRF-induced ERK phosphorylation. Gene expression analysis showed high levels of EPAC2 mRNA and protein but low levels of EPAC1. Knockdown of EPAC2 expression by the use of specific siRNAs abolished CRF- and forskolin-induced ERK phosphorylation. The current study demonstrates a clear cAMP-dependent but PKA-independent mechanism underlying CRF-induced ERK activity that proceeds via EPAC2 signalling. Further research will provide more insight in the role of EPAC2 in CRF signalling.

Citing Articles

Basolateral amygdala corticotropin-releasing factor receptor type 1 regulates context-cocaine memory strength during reconsolidation in a sex-dependent manner.

Ritchie J, Walters J, Galliou J, Christian R, Qi S, Savenkova M Neuropharmacology. 2021; 200:108819.

PMID: 34610289 PMC: 8550898. DOI: 10.1016/j.neuropharm.2021.108819.


Expression and Role of Thyrotropin Receptors in Proopiomelanocortin-Producing Pituitary Cells.

Previde R, Wang K, Smiljanic K, Janjic M, Nunes M, Stojilkovic S Thyroid. 2020; 31(5):850-858.

PMID: 33191870 PMC: 8110008. DOI: 10.1089/thy.2020.0222.


Agonist bias and agonist-dependent antagonism at corticotrophin releasing factor receptors.

Tasma Z, Wills P, Hay D, Walker C Pharmacol Res Perspect. 2020; 8(3):e00595.

PMID: 32529807 PMC: 7290078. DOI: 10.1002/prp2.595.


Evaluation of Serum Urocortin 2 Levels in Patients with Hypertension.

Aslan G, Aytekin S High Blood Press Cardiovasc Prev. 2020; 27(1):35-42.

PMID: 31925709 DOI: 10.1007/s40292-019-00357-x.


CRF Receptor Signaling via the ERK1/2-MAP and Akt Kinase Cascades: Roles of Src, EGF Receptor, and PI3-Kinase Mechanisms.

Parra-Mercado G, Fuentes-Gonzalez A, Hernandez-Aranda J, Diaz-Coranguez M, Dautzenberg F, Catt K Front Endocrinol (Lausanne). 2020; 10:869.

PMID: 31920979 PMC: 6921279. DOI: 10.3389/fendo.2019.00869.